|Tested species reactivity||Human|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Rabbit / IgG|
|Immunogen||A synthetic peptide from C-terminus of human c-erbB-4 protein|
|Storage buffer||PBS, pH 7.6, with 0.2% BSA|
|Contains||15mM sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
|Western Blot (WB)||2-4 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA5-16789 targets HER-4 in IHC (P) and WB applications and shows reactivity with Human samples.
The PA5-16789 immunogen is a synthetic peptide from C-terminus of human c-erbB-4 protein.
c-erbB-4 is the fourth member of class I receptor kinase family. HER-4 is most predominantly expressed in several breast carcinoma cell lines, and in normal skeletal muscle, heart, pituitary, brain, and cerebellum. Breast tumor cell lines T47-D, MDA-MB-453, BT-474 and H3396 are found to have the highest levels of mRNA, and intermediate levels are seen in MCF-7, MDA-MB-330 and MDA-MB-361. Expression of erbB-4 is low or absent in some breast tumor cell lines such as MDA-MB-231, MDA-MB-157, MDA-MB-468, and SKBR-3.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Expression of the EGF family in gastric cancer: downregulation of HER4 and its activating ligand NRG4.
PA5-16789 was used in immunohistochemistry - paraffin section to study EGF family expression in gastrici cancer and the downregulation of HER4 and its activating ligand NRG4
|Nielsen TO,Friis-Hansen L,Poulsen SS,Federspiel B,Sorensen BS||PloS one (9:null)||2014|
Characterisation of HER heterodimers in breast cancer using in situ proximity ligation assay.
PA5-16789 was used in immunohistochemistry to use an in situ proximity ligation assay to study the heterodimerization status of HER2 in breast cancer tissue samples
|Barros FF,Abdel-Fatah TM,Moseley P,Nolan CC,Durham AC,Rakha EA,Chan S,Ellis IO,Green AR||Breast cancer research and treatment (144:273)||2014|
Prognostic value of epidermal growth factor receptors in gastric cancer: a survival analysis by Weibull model incorporating long-term survivors.
PA5-16789 was used in immunohistochemistry to study the prognostic value of the immunohistochemical expression of HER1-4 in gastric cancer
|Jácome AA,Wohnrath DR,Scapulatempo Neto C,Carneseca EC,Serrano SV,Viana LS,Nunes JS,Martinez EZ,Santos JS||Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association (17:76)||2014|
The HER4 isoform JM-a/CYT2 relates to improved survival in bladder cancer patients but only if the estrogen receptor ¿ is not expressed.
PA5-16789 was used in immunohistochemistry to study the improved survival of bladder cancer patients expressing the Jma/CYT2 isoform of HER4 in the absence of ER-alpha co-expression
|Munk M,Memon A,Poulsen SS,Borre M,Nexo E,Sorensen BS||Scandinavian journal of clinical and laboratory investigation (73:503)||2013|
Assessment of protein expression and gene status of human epidermal growth factor receptor (HER) family molecules in ameloblastomas.
PA5-16789 was used in immunohistochemistry to study the expression of HER family members in ameloblastomas
|Oikawa M,Miki Y,Shimizu Y,Kumamoto H||Journal of oral pathology and medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (42:424)||2013|
Immunohistochemical analysis of the monoclonal antibody 4B5 in breast tissue expressing human epidermal growth factor receptor 4 (HER4).
PA5-16789 was used in immunohistochemistry to study the utility of the 4B5 monoclonal antibody for clinical HER2 status determination in breast tissue expressing HER4
|Jay JI,Brunhoeber PS,Smith MH,Williams RR,Sugarman MC,Free HL,Tast DE||Histopathology (62:563)||2013|
Activated HER-receptors in predicting outcome of ER-positive breast cancer patients treated with adjuvant endocrine therapy.
PA5-16789 was used in immunohistochemistry to study the prognostic value of measuring activated HER receptors in patients with ER-positive breast cancer receiving adjuvant hormone therapy
|Larsen MS,Bjerre K,Lykkesfeldt AE,Giobbie-Hurder A,Laenkholm AV,Henriksen KL,Ejlertsen B,Rasmussen BB||Breast (Edinburgh, Scotland) (21:662)||2012|
Evaluation of the antitumor activity of dacomitinib in models of human bladder cancer.
PA5-16789 was used in western blot to study the efficacy and tolerability of the irreversible tyrosine kinase inhibitor dacomitinib in human bladder cancer models
|Grivas PD,Day KC,Karatsinides A,Paul A,Shakir N,Owainati I,Liebert M,Kunju LP,Thomas D,Hussain M,Day ML||Molecular medicine (Cambridge, Mass.) (19:367)||2013|